# Hepatitis B Virus Infection Is Associated with a Higher Risk of Liver Metastasis in Gastric Cancer

**Authors:** Songting Zhu, Mengmeng Jiang, Yanyan Chen, Yongfeng Ding, Haiyong Wang, Lisong Teng

PMC · DOI: 10.3390/curroncol33030179 · 2026-03-21

## TL;DR

This study finds that hepatitis B virus infection increases the risk of liver metastasis in gastric cancer patients.

## Contribution

The study demonstrates a novel association between HBV infection and liver metastasis in gastric cancer.

## Key findings

- HBV+ patients had a higher prevalence of liver metastasis (25.3%) compared to HBV− patients (15.8%).
- HBV infection was an independent risk factor for gastric cancer liver metastasis (OR = 2.563).
- Both chronic and occult HBV infections were linked to higher liver metastasis rates.

## Abstract

Hepatitis B virus (HBV) is not only associated with primary liver cancer but also increases the risk of other malignancies, and may be linked to an increased risk of liver metastasis in colorectal cancer. However, the relationship between HBV infection and liver metastasis in gastric cancer (GCLM) remains unclear. This retrospective study focuses on the relationship between HBV infection and liver metastasis in gastric cancer. This study shows that hepatitis B virus infection increases the risk of liver metastasis in gastric cancer patients. Patients with HBV infection should receive careful monitoring for liver metastasis to improve clinical management and outcomes.

Background: Hepatitis B virus infection has been linked to liver cancer and may influence metastasis in other malignancies, but its role in gastric cancer liver metastasis (GCLM) is unclear. Methods: We retrospectively analyzed 776 gastric cancer patients with HBV testing. HBV infection was defined as HBsAg+ (chronic HBV, CHB) or HBsAg− with HBcAb/HBeAb+ (occult HBV, OHB). Among the 776 patients, 300 (38.6%) were classified as HBV+. The association between HBV infection and GCLM was evaluated, and propensity score matching (PSM) was performed to adjust for age and gender. Furthermore, the impact of HBV infection on overall survival (OS) was analyzed. Results: GCLM occurred in 19.5% of patients. HBV+ patients had a higher GCLM prevalence than HBV− patients (25.3% vs. 15.8%; p = 0.001), persisting after PSM (25.3% vs. 15.3%; p = 0.002). HBV infection was an independent risk factor for GCLM (OR = 2.563, p < 0.001). Both OHB and CHB groups showed significantly higher GCLM rates than HBV− patients in univariate and multivariate analyses. However, OS did not differ between groups (p = 0.737). Conclusion: HBV infection significantly increases the risk of liver metastasis in gastric cancer. Enhanced surveillance for liver metastasis is warranted in these patients.

## Linked entities

- **Diseases:** Hepatitis B (MONDO:0005344), liver cancer (MONDO:0002691), gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** GGTLC5P (gamma-glutamyltransferase light chain 5 pseudogene) [NCBI Gene 653590] {aka GGT}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, GPT (glutamic--pyruvic transaminase) [NCBI Gene 2875] {aka AAT1, ALT, ALT1, GPT1, SGPT}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}
- **Diseases:** death (MESH:D003643), TN (MESH:C562719), gastric carcinogenesis (MESH:D063646), cancer (MESH:D009369), leukemia (MESH:D007938), liver tumors (MESH:D008113), Metastasis (MESH:D009362), gastrointestinal tumors (MESH:D005770), CHB (MESH:D019694), injury to (MESH:D014947), HBV Infection (MESH:D006509), infection (MESH:D007239), pancreatic cancer (MESH:D010190), gastric precancerous lesions (MESH:D011230), liver cirrhosis (MESH:D008103), colorectal cancer (MESH:D015179), esophagus cancer (MESH:D004938), cervical cancer (MESH:D002583), GCLM (MESH:D013274), H. pylori infection (MESH:D016481), liver cancer (MESH:D006528), Liver (MESH:D017093), infectious liver diseases (MESH:D003141), non-Hodgkin lymphoma (MESH:D008228), liver-related diseases (MESH:D008107)
- **Chemicals:** bilirubin (MESH:D001663), DBIL (-)
- **Species:** Hepatitis B virus (no rank) [taxon 10407], Homo sapiens (human, species) [taxon 9606], Helicobacter pylori (species) [taxon 210]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025660/full.md

---
Source: https://tomesphere.com/paper/PMC13025660